IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Purchased by ST Germain D J Co. Inc.

ST Germain D J Co. Inc. boosted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 517.2% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 179 shares of the company’s stock after purchasing an additional 150 shares during the quarter. ST Germain D J Co. Inc.’s holdings in IDEXX Laboratories were worth $74,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in IDXX. Wealth Enhancement Advisory Services LLC grew its holdings in shares of IDEXX Laboratories by 0.4% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 29,751 shares of the company’s stock worth $12,300,000 after acquiring an additional 117 shares during the period. First Hawaiian Bank grew its holdings in IDEXX Laboratories by 32.5% in the fourth quarter. First Hawaiian Bank now owns 665 shares of the company’s stock valued at $275,000 after purchasing an additional 163 shares during the last quarter. Westwind Capital increased its position in shares of IDEXX Laboratories by 2.8% in the fourth quarter. Westwind Capital now owns 44,662 shares of the company’s stock valued at $18,465,000 after buying an additional 1,211 shares in the last quarter. Insight Wealth Strategies LLC raised its stake in shares of IDEXX Laboratories by 230.5% during the 4th quarter. Insight Wealth Strategies LLC now owns 10,096 shares of the company’s stock worth $4,174,000 after buying an additional 7,041 shares during the last quarter. Finally, Nordea Investment Management AB boosted its position in shares of IDEXX Laboratories by 5.5% in the 4th quarter. Nordea Investment Management AB now owns 6,409 shares of the company’s stock worth $2,658,000 after buying an additional 334 shares in the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Trading Down 3.3 %

NASDAQ IDXX opened at $418.05 on Friday. The company has a market cap of $34.23 billion, a P/E ratio of 40.31, a P/E/G ratio of 3.94 and a beta of 1.36. IDEXX Laboratories, Inc. has a 12 month low of $398.50 and a 12 month high of $583.39. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.42 and a quick ratio of 1.03. The company has a 50-day moving average of $423.76 and a 200-day moving average of $460.18.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Thursday, October 31st. The company reported $2.80 EPS for the quarter, topping the consensus estimate of $2.69 by $0.11. The firm had revenue of $975.50 million during the quarter, compared to analyst estimates of $980.32 million. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. IDEXX Laboratories’s revenue for the quarter was up 6.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.53 earnings per share. As a group, equities analysts predict that IDEXX Laboratories, Inc. will post 10.44 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Sophie V. Vandebroek sold 344 shares of the business’s stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the completion of the sale, the director now owns 905 shares in the company, valued at approximately $380,498.20. The trade was a 27.54 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 2.11% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on IDXX shares. JPMorgan Chase & Co. reduced their price target on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. Piper Sandler reiterated a “neutral” rating and set a $435.00 target price (down previously from $520.00) on shares of IDEXX Laboratories in a report on Monday, November 4th. Leerink Partners assumed coverage on IDEXX Laboratories in a research report on Monday, December 2nd. They set an “outperform” rating and a $500.00 price target for the company. StockNews.com upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Thursday, November 28th. Finally, Barclays cut their target price on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating for the company in a research note on Monday, November 4th. Two equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $539.63.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.